OraSure Technologies

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in May 2000 in and is headquartered in Bethlehem, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OraSure Technologies excels in Q4 2022, eyes strategic partnerships for growth

OraSure Technologies showcased robust financial performance, operational efficiency, and strategic partnerships in Q4 2022.
While facing challenges in margin structure and international mix, the company is focused on core growth and cost-saving initiatives.
Opportunities lie in business unit consolidation, product innovation, and strategic partnerships for future growth and profitability.

OraSure Technologies reports record Q1 revenue, focuses on growth

OraSure Technologies delivered strong Q1 results with record revenue and improved margins, driven by IntelliSwab sales. While facing challenges in product diversification and cost management, the company's focus on efficiency and innovation presents growth opportunities. Strategic partnerships and a solid financial position further support its growth trajectory.

OraSure Technologies reports robust Q2 earnings, eyes growth opportunities ahead

OraSure Technologies delivered strong financial performance in Q2 2023, with revenue growth, operating cash flow, and strategic advancements across key business segments.
While facing challenges in margin improvement and revenue forecasting, the company's focus on cost reductions, operational efficiencies, and growth strategies positions it for long-term success.
By leveraging strengths in core business areas, collaborations, and innovation, OraSure is well-positioned to capitalize on opportunities for accelerated growth and market expansion.

OraSure Technologies excels in Q3 with revenue growth and strategic milestones

OraSure Technologies demonstrated strong financial performance and operational efficiency in Q3 2023, with notable revenue growth and cash flow generation.
While facing challenges in margin moderation and operating expenses, the company's strategic focus on innovation and partnerships presents growth opportunities.
Overall, OraSure's successful milestones, revenue diversification, and cost management efforts position it for continued growth and market leadership.

OraSure Technologies posts strong Q4 results amidst market challenges

OraSure Technologies demonstrated robust financial performance in Q4 2023, driven by revenue diversification and strategic cost-saving initiatives.
While facing challenges in muted core revenue growth for Q1 2024, the company remains confident in its long-term growth prospects.
Strategic partnerships and investments present opportunities for revenue expansion and market penetration in key segments.

OraSure Technologies surpasses Q1 revenue targets, eyes operational breakeven

OraSure Technologies delivered strong financial performance in Q1, exceeding revenue guidance and showcasing core revenue strength.
While facing challenges in business transitions and cost management, the company's strategic focus on efficiency and growth presents opportunities.
With a solid cash position, key partnerships, and a clear roadmap to breakeven in operating cash flow, OraSure is poised for future success.

OraSure Technologies reports robust Q2 results and eyes global expansion

OraSure Technologies delivered strong Q2 financial results with revenue near guidance ranges and operational improvements.
The company faces challenges in cost restructuring and gross margin outlook but sees growth opportunities in new products and partnerships.
International revenue growth, strategic partnerships, and product extensions position OraSure for future success and market expansion.

OraSure Technologies reports stable Q3 performance and eyes growth

OraSure Technologies navigated Q3 with stable financial performance, focusing on core revenue growth and strategic business realignment.
The company's emphasis on innovation, new market entry, and financial strength positions it well for future growth and market expansion.
While challenges like revenue decline and business transitions exist, OraSure Technologies is proactively addressing them to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offers oral fluid diagnostic products and specimen collection devices. The DNAG segment produces specimen collection kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome, and animal genetics markets. The company was founded by Michael J. Gausling in 2000 in and is headquartered in Bethlehem, PA.

BETHLEHEM, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2023 financial results and certain business developments for 5:00 pm ET on Tuesday, November 7, 2023.

OraSure to Announce Third Quarter 2023 Financial Results and Host Earnings Call on November 7th

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jason Plagman – Vice President-Investor Relations Carrie Eglinton Manner – President and Chief Executive Officer Ken McGrath – Chief Financial Officer Conference Call Participants Jacob Johnson – Stephens Operator Good day, and thank you for standing by. Welcome to the OraSure Technologies 2023 Second Quarter Earnings Conference Call.

OraSure Technologies, Inc. (OSUR) Q2 2023 Earnings Call Transcript

OraSure Technologies (OSUR) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.

OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates

InteliSwab® test revenue of $47.5 million in Q2 Q2 Core revenue of $37.9 million grew 4% sequentially and 3% year-over-year Q2 GAAP EPS of $(0.07); Q2 Non-GAAP EPS of $0.09 Grew cash balance to $185.9 million as o f June 30, 2023 InteliSwab® orders are expected to generate at least $70 million of revenue in second half of 2023 On track to achieve operating cash flow breakeven on core business by end of 2024 BETHLEHEM, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced its financial results for the three months ended June 30, 2023.

OraSure Reports Q2 ‘23 Revenue of $85.4 Million; Core Revenue Grows 3% Year-over-Year

BETHLEHEM, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced today the election of Robert W. McMahon, CMA, MBA, to the Company's Board of Directors, effective July 31, 2023. Including McMahon, the company's Board of Directors has seven members.

OraSure Technologies Elects Robert McMahon to the Board of Directors

BETHLEHEM, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a global leader in point-of-care and at-home diagnostic testing, as well as non-invasive self-sampling technologies and microbiome-focused biocomputational solutions, announced today that a major health economics study featuring its Colli-Pee® device has been published in the biomedical journal “BMJ Open.” This study, conducted by experts from Aquarius Population Health Limited in London and the University of Manchester, presents valuable insights into the cost-effectiveness of self-sampling for routine human papillomavirus (HPV) primary cervical cancer screening using the Colli-Pee® UCM® self-collection device.

Study Concludes Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access

OSUR shares had mounted an impressive 54% rally for 2023 through to May 10, when the first-quarter results update spooked investors.

OraSure Technologies' CFO Makes Bold Insider Purchase, Reigniting Investor Confidence

OraSure came in with another strong quarter with upsides against the consensus at the top and bottom lines. The firm is concentrating heavily on capital allocation and will close its overseas InteliSwab production lines.

OraSure: Valuation Upside On The Table At 16x Forward P/E

Today, we take our first look at OraSure Technologies, Inc., which has seen a huge and recent surge of revenues. However, this was almost entirely due to Covid-related sales which are projected to fall dramatically in the quarters ahead.

OraSure Technologies: As Good As It Gets

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q1 2023 Earnings Conference Call May 10, 2023 5:00 PM ET Company Participants Scott Gleason - Head of Investor Relations Carrie Manner - President & Chief Executive Officer Ken McGrath - Chief Financial Officer Conference Call Participants Casey Woodring - JPMorgan Operator Good day, and thank you for standing-by. Welcome to the OraSure Technologies Earnings Conference Call.

OraSure Technologies, Inc. (OSUR) Q1 2023 Earnings Call Transcript

OraSure Technologies (OSUR) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to loss of $0.28 per share a year ago.

OraSure Technologies (OSUR) Q1 Earnings and Revenues Beat Estimates

InteliSwab ® test revenue of $118.3 million in Q1, up 33% sequentially;  Company delivers cost savings and begins to taper InteliSwab ® test production and expenses

OraSure Reports 1Q23 Record Revenue of $155.0 Million; Announces New Collaborations as Company Increasingly Focuses on Core Growth

BETHLEHEM, Pa., May 03, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2023 first quarter financial results and certain business developments for 5:00 p.m. ET (2:00 p.m. PT) on Wednesday, May 10, 2023.

2023 First Quarter Earnings Conference Call Wednesday, May 10, 2023, 5:00 p.m. ET

Here is how OraSure Technologies (OSUR) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Is OraSure Technologies (OSUR) Outperforming Other Medical Stocks This Year?

OraSure (OSUR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

OraSure (OSUR) Stock Jumps 9.3%: Will It Continue to Soar?

Compania de Minas Buenaventura

Vipshop Hlds

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. OraSure Technologies (OSUR), Compa?

3 Low-Beta Stocks to Buy to Combat the Volatile Market

Immersion

Payoneer Global

March Madness is here, and the markets are offering buy opportunities for investors wanting to take a calculated risk and take advantage of market corrections. Unlike both SVB Financial and First Republic which had Quant Sell ratings, the small-cap stocks recommended in this article possess solid investment fundamentals and excellent growth track records.

March Madness: My Final 4 Small Cap Stocks Under $10

OraSure has robust growth throughout the P&L, cash flows and balance sheet. Core business exhibiting remarkable upsides without Covid-19 revenues.

OraSure: Revising To Buy Following Extensive Growth Route

OraSure (OSUR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for OraSure (OSUR) Stock

Investors applauded the diagnostics company's Q4 update.

Why OraSure Technologies Stock Is Jumping Today

OraSure Technologies, Inc. (NASDAQ:OSUR ) Q4 2022 Earnings Conference Call February 14, 2023 5:00 PM ET Company Participants Scott Gleason - SVP, IR & Corporate Communications Carrie Manner - President, CEO & Director Kenneth McGrath - CFO Conference Call Participants Vijay Kumar - Evercore ISI Elizabeth Speyer - Citigroup Brandon Couillard - Jefferies Jacob Johnson - Stephens Inc. Casey Woodring - JPMorgan Chase & Co. Andrew Cooper - Raymond James & Associates Operator Good day, and thank you pray. Welcome to the OraSure Technologies 2022 Fourth Quarter Earnings Conference Call.

OraSure Technologies, Inc. (OSUR) Q4 2022 Earnings Call Transcript

OraSure (OSUR) delivered earnings and revenue surprises of 2,000% and 26.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Surpasses Q4 Earnings and Revenue Estimates

InteliSwab ® revenue of $88.9 million in Q4, up 12% sequentially; wins two new federal government contracts extending the tail on InteliSwab ® revenue

OraSure Reports 4Q22 Record Revenue of $123.1 Million Growing 94% Year-Over-Year; Positions for Longer-Term Growth and Profitability

BETHLEHEM, Pa., Feb. 07, 2023 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering 2022 fourth quarter financial results and certain business developments for 5:00 pm ET (2:00 pm PT) on Tuesday, February 14, 2023.

2022 Fourth Quarter Earnings Conference Call Tuesday, February 14, 2023, 5:00 p.m. ET

Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day Company to Ring Nasdaq Closing Bell in New York City in Observation of World AIDS Day

News for OraSure Technologies Stock (OSUR)